clinical trial · NCT07413679
Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
Alexion Pharmaceuticals, Inc.·—·active not recruiting·n = 50
Paroxysmal Nocturnal HemoglobinuriaPNHDanicopan
brief summary
This is a noninterventional cohort study using primary and secondary data from the International PNH Interest Group (IPIG) PNH registry. It is designed to characterize the long-term safety and tolerability of danicopan as add-on therapy to eculizumab or ravulizumab in adult participants with PNH.
started
Aug 18, 2025
primary completion
Jul 1, 2029
completion
Jul 1, 2029
last updated
Feb 17, 2026
official title
An Observational Study to Assess Long-Term Safety of Danicopan Add-on Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol